Teva Pharmaceutical to Stop Making Propofol, Could Exacerbate Shortage

Teva Pharmaceutical Industries told the U.S. Food and Drug Administration it will stop manufacturing propofol, which could further exacerbate a months-long shortage of the anesthetic, according to a report in the Wall Street Journal.

Advertisement

The Israeli company recalled some vials of the drug in July 2009, and the FDA recently sent the company a warning letter about violations found at its Irvine, Calif., plant, according to the report.

APP Pharmaceuticals and Hospira are both manufacturing and distributing propofol. The FDA allowed APP to import a similar European product earlier this year after the American Society of Anesthesiologists raised concerns over the shortage.

Read the Wall Street Journal’s report on the propofol shortage.

Advertisement

Next Up in Legal & Regulatory Issues

  • Changes to Medicaid eligibility and financing, Connecticut’s certificate-of-need overhaul and Maryland’s new hospital staffing framework are among the healthcare-related laws…

  • After a brief post-pandemic lull, hospital consolidation is accelerating again, with large health systems expanding across state lines, absorbing independent…

Advertisement

Comments are closed.